|
private:medasensebiometricsltd.
|
399874
|
May 29th, 2019 12:00AM
|
Medasense Biometrics Ltd.
|
1.6K
|
39.00
|
Open
|
Medical Devices
|
May 29th, 2019 06:19PM
|
May 29th, 2019 06:19PM
|
Medasense is a developer of innovative medical devices and applications in the field of objective pain monitoring.
Considering the complex nature of pain, Medasense technology uses a unique multi-parametric approach and advanced artificial intelligence algorithms to convert complicated data into a patient's “Signature of Pain”.
Following extensive multidisciplinary research, the company has developed the novel NOL ™ index (Nociception Level Index). This patented technology platform enables an objective assessment of the physiological response to pain (nociception). NOL™ Index, is the only pain assessment index based on dozens of pain-related physiological parameters and clinically validated as superior to other nociception/pain indicators .
The PMD-200™ pain monitoring device is Medasense's flagship product. It is based on the patented NOL™ technology, and provides objective, non-invasive, and continuous monitoring of the physiological response to pain.
Medasense's goal is to personalize and optimize pain care in all relevant clinical scenarios and settings.
|
Open
|
Pain Monitoring, Nociception Monitoring, Analgesia Monitoring, Pain Intelligence, anesthesiology, General Anesthesiology
|
Open
|
4 Hachilazon St, 7th floor
|
Ramat Gan
|
Hamerkaz
|
IL
|
5252268
|
|
Medasense Biometrics Ltd.
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:medasensebiometricsltd.
|
399874
|
Feb 17th, 2018 12:00AM
|
Medasense Biometrics Ltd.
|
823
|
26.00
|
Open
|
Medical Devices
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Medasense is a developer of innovative medical devices and applications in the field of objective pain monitoring.
Considering the complex nature of pain, Medasense technology uses a unique multi-parametric approach and advanced artificial intelligence algorithms to convert complicated data into a patient's “Signature of Pain”.
Following extensive multidisciplinary research, the company has developed the novel NOL ™ index (Nociception Level Index). This patented technology platform enables an objective assessment of the physiological response to pain (nociception). NOL™ Index, is the only pain assessment index based on dozens of pain-related physiological parameters and clinically validated as superior to other nociception/pain indicators .
The PMD-200™ pain monitoring device is Medasense's flagship product. It is based on the patented NOL™ technology, and provides objective, non-invasive, and continuous monitoring of the physiological response to pain.
Medasense's goal is to personalize and optimize pain care in all relevant clinical scenarios and settings.
|
|
|
|
|
|
|
|
|
|
Medasense Biometrics Ltd.
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:medasensebiometricsltd.
|
399874
|
Feb 16th, 2018 12:00AM
|
Medasense Biometrics Ltd.
|
823
|
26.00
|
Open
|
Medical Devices
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Medasense is a developer of innovative medical devices and applications in the field of objective pain monitoring.
Considering the complex nature of pain, Medasense technology uses a unique multi-parametric approach and advanced artificial intelligence algorithms to convert complicated data into a patient's “Signature of Pain”.
Following extensive multidisciplinary research, the company has developed the novel NOL ™ index (Nociception Level Index). This patented technology platform enables an objective assessment of the physiological response to pain (nociception). NOL™ Index, is the only pain assessment index based on dozens of pain-related physiological parameters and clinically validated as superior to other nociception/pain indicators .
The PMD-200™ pain monitoring device is Medasense's flagship product. It is based on the patented NOL™ technology, and provides objective, non-invasive, and continuous monitoring of the physiological response to pain.
Medasense's goal is to personalize and optimize pain care in all relevant clinical scenarios and settings.
|
|
|
|
|
|
|
|
|
|
Medasense Biometrics Ltd.
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:medasensebiometricsltd.
|
399874
|
Feb 15th, 2018 12:00AM
|
Medasense Biometrics Ltd.
|
823
|
26.00
|
Open
|
Medical Devices
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Medasense is a developer of innovative medical devices and applications in the field of objective pain monitoring.
Considering the complex nature of pain, Medasense technology uses a unique multi-parametric approach and advanced artificial intelligence algorithms to convert complicated data into a patient's “Signature of Pain”.
Following extensive multidisciplinary research, the company has developed the novel NOL ™ index (Nociception Level Index). This patented technology platform enables an objective assessment of the physiological response to pain (nociception). NOL™ Index, is the only pain assessment index based on dozens of pain-related physiological parameters and clinically validated as superior to other nociception/pain indicators .
The PMD-200™ pain monitoring device is Medasense's flagship product. It is based on the patented NOL™ technology, and provides objective, non-invasive, and continuous monitoring of the physiological response to pain.
Medasense's goal is to personalize and optimize pain care in all relevant clinical scenarios and settings.
|
|
|
|
|
|
|
|
|
|
Medasense Biometrics Ltd.
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:medasensebiometricsltd.
|
399874
|
Feb 14th, 2018 12:00AM
|
Medasense Biometrics Ltd.
|
823
|
26.00
|
Open
|
Medical Devices
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Medasense is a developer of innovative medical devices and applications in the field of objective pain monitoring.
Considering the complex nature of pain, Medasense technology uses a unique multi-parametric approach and advanced artificial intelligence algorithms to convert complicated data into a patient's “Signature of Pain”.
Following extensive multidisciplinary research, the company has developed the novel NOL ™ index (Nociception Level Index). This patented technology platform enables an objective assessment of the physiological response to pain (nociception). NOL™ Index, is the only pain assessment index based on dozens of pain-related physiological parameters and clinically validated as superior to other nociception/pain indicators .
The PMD-200™ pain monitoring device is Medasense's flagship product. It is based on the patented NOL™ technology, and provides objective, non-invasive, and continuous monitoring of the physiological response to pain.
Medasense's goal is to personalize and optimize pain care in all relevant clinical scenarios and settings.
|
|
|
|
|
|
|
|
|
|
Medasense Biometrics Ltd.
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:medasensebiometricsltd.
|
399874
|
Feb 13th, 2018 12:00AM
|
Medasense Biometrics Ltd.
|
823
|
26.00
|
Open
|
Medical Devices
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Medasense is a developer of innovative medical devices and applications in the field of objective pain monitoring.
Considering the complex nature of pain, Medasense technology uses a unique multi-parametric approach and advanced artificial intelligence algorithms to convert complicated data into a patient's “Signature of Pain”.
Following extensive multidisciplinary research, the company has developed the novel NOL ™ index (Nociception Level Index). This patented technology platform enables an objective assessment of the physiological response to pain (nociception). NOL™ Index, is the only pain assessment index based on dozens of pain-related physiological parameters and clinically validated as superior to other nociception/pain indicators .
The PMD-200™ pain monitoring device is Medasense's flagship product. It is based on the patented NOL™ technology, and provides objective, non-invasive, and continuous monitoring of the physiological response to pain.
Medasense's goal is to personalize and optimize pain care in all relevant clinical scenarios and settings.
|
|
|
|
|
|
|
|
|
|
Medasense Biometrics Ltd.
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:medasensebiometricsltd.
|
399874
|
Feb 12th, 2018 12:00AM
|
Medasense Biometrics Ltd.
|
823
|
26.00
|
Open
|
Medical Devices
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Medasense is a developer of innovative medical devices and applications in the field of objective pain monitoring.
Considering the complex nature of pain, Medasense technology uses a unique multi-parametric approach and advanced artificial intelligence algorithms to convert complicated data into a patient's “Signature of Pain”.
Following extensive multidisciplinary research, the company has developed the novel NOL ™ index (Nociception Level Index). This patented technology platform enables an objective assessment of the physiological response to pain (nociception). NOL™ Index, is the only pain assessment index based on dozens of pain-related physiological parameters and clinically validated as superior to other nociception/pain indicators .
The PMD-200™ pain monitoring device is Medasense's flagship product. It is based on the patented NOL™ technology, and provides objective, non-invasive, and continuous monitoring of the physiological response to pain.
Medasense's goal is to personalize and optimize pain care in all relevant clinical scenarios and settings.
|
|
|
|
|
|
|
|
|
|
Medasense Biometrics Ltd.
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:medasensebiometricsltd.
|
399874
|
Feb 11th, 2018 12:00AM
|
Medasense Biometrics Ltd.
|
823
|
26.00
|
Open
|
Medical Devices
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Medasense is a developer of innovative medical devices and applications in the field of objective pain monitoring.
Considering the complex nature of pain, Medasense technology uses a unique multi-parametric approach and advanced artificial intelligence algorithms to convert complicated data into a patient's “Signature of Pain”.
Following extensive multidisciplinary research, the company has developed the novel NOL ™ index (Nociception Level Index). This patented technology platform enables an objective assessment of the physiological response to pain (nociception). NOL™ Index, is the only pain assessment index based on dozens of pain-related physiological parameters and clinically validated as superior to other nociception/pain indicators .
The PMD-200™ pain monitoring device is Medasense's flagship product. It is based on the patented NOL™ technology, and provides objective, non-invasive, and continuous monitoring of the physiological response to pain.
Medasense's goal is to personalize and optimize pain care in all relevant clinical scenarios and settings.
|
|
|
|
|
|
|
|
|
|
Medasense Biometrics Ltd.
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:medasensebiometricsltd.
|
399874
|
Feb 10th, 2018 12:00AM
|
Medasense Biometrics Ltd.
|
823
|
26.00
|
Open
|
Medical Devices
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Medasense is a developer of innovative medical devices and applications in the field of objective pain monitoring.
Considering the complex nature of pain, Medasense technology uses a unique multi-parametric approach and advanced artificial intelligence algorithms to convert complicated data into a patient's “Signature of Pain”.
Following extensive multidisciplinary research, the company has developed the novel NOL ™ index (Nociception Level Index). This patented technology platform enables an objective assessment of the physiological response to pain (nociception). NOL™ Index, is the only pain assessment index based on dozens of pain-related physiological parameters and clinically validated as superior to other nociception/pain indicators .
The PMD-200™ pain monitoring device is Medasense's flagship product. It is based on the patented NOL™ technology, and provides objective, non-invasive, and continuous monitoring of the physiological response to pain.
Medasense's goal is to personalize and optimize pain care in all relevant clinical scenarios and settings.
|
|
|
|
|
|
|
|
|
|
Medasense Biometrics Ltd.
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:medasensebiometricsltd.
|
399874
|
Feb 9th, 2018 12:00AM
|
Medasense Biometrics Ltd.
|
823
|
26.00
|
Open
|
Medical Devices
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
Medasense is a developer of innovative medical devices and applications in the field of objective pain monitoring.
Considering the complex nature of pain, Medasense technology uses a unique multi-parametric approach and advanced artificial intelligence algorithms to convert complicated data into a patient's “Signature of Pain”.
Following extensive multidisciplinary research, the company has developed the novel NOL ™ index (Nociception Level Index). This patented technology platform enables an objective assessment of the physiological response to pain (nociception). NOL™ Index, is the only pain assessment index based on dozens of pain-related physiological parameters and clinically validated as superior to other nociception/pain indicators .
The PMD-200™ pain monitoring device is Medasense's flagship product. It is based on the patented NOL™ technology, and provides objective, non-invasive, and continuous monitoring of the physiological response to pain.
Medasense's goal is to personalize and optimize pain care in all relevant clinical scenarios and settings.
|
|
|
|
|
|
|
|
|
|
Medasense Biometrics Ltd.
|
Health Care
|
Pharmaceuticals & Biotechnology
|